Finally, safe and effective treatment options for hepatitis C in hemodialysis patients

Affiliations

Editorial

Kalyan Ram Bhamidimarri et al. J Hepatol. 2016 Jul.

. 2016 Jul;65(1):7-10.

doi: 10.1016/j.jhep.2016.04.003. Epub 2016 Apr 9.

¹ University of Miami, Miami, FL, USA.
² University of Miami, Miami, FL, USA. Electronic address: PMartin2@med.miami.edu.

No abstract available

Keywords: Direct acting antivirals; End-stage renal disease; HCV.

Comment on

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G. Desnoyer A, et al. J Hepatol. 2016 Jul;65(1):40-47. doi: 10.1016/j.jhep.2016.02.044. Epub 2016 Mar 4. J Hepatol. 2016. PMID: 26952005